Title	Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
ID	3567758
External ID	120000729
Author
Published Date	Oct. 24, 2024, 7 a.m.
Summary	Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film Aquestive Therapeutics, Inc. Aquestive Therapeuti
Tags	None
URL	No URL
Sentiment	Negative: 0.03148 Neutral: 0.91539 Positive: 0.05313
Relevance	0.01005

Content ID	1884608
Key	144fde26-b40f-483d-90f0-b8b4999cde1e
Content	Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film Aquestive Therapeutics, Inc. Aquestive Therapeutics, Inc. Thu, Oct 24, 2024, 3:00 PM 11 min read In This Article: AQST +2.05% Completed OAS challenge study meets both primary and secondary endpoints Demonstrates rapid resolution of allergen-related symptoms beginning two minutes after administration Pharmacokinetic (PK) profile after allergen exposure comparable to non-allergen PK profile On track for a pre-NDA meeting on Anaphylm in Q4 2024 WARREN, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced positive topline results from its Oral Allergy Syndrome (OAS) challenge study for Anaphylm™ (epinephrine) Sublingual Film. This marks the completion of the final supportive adult study in the Anaphylm development program prior to meeting with the U.S. Food and Drug Administration (FDA). The OAS challenge study was designed as a two-part investigation to evaluate the PK and pharmacodynamics (PD) of Anaphylm in adults with allergen-induced oral physiological change. Part 1 of the study enrolled subjects with confirmed OAS into a three-period study with the following arms: (1) Anaphylm with allergen exposure (n=18 single dose; n=18 repeat dose); (2) Anaphylm without allergen exposure (n=15 single dose; n=13 repeat dose); and (3) Adrenalin intramuscular (IM) injection without allergen exposure (n=18 single dose; n=17 repeat dose). Part 2 was an optional follow-on study to Part 1. Six subjects who received single dose in Part 1 received repeat dose; and six subjects who received repeat dose in Part 1 received single dose. Anaphylm was administered with allergen exposure, while IM was administered without allergen exposure. During allergen exposure arms in Parts 1 and 2, subjects were exposed to a fruit they were known to be allergic to, and the resulting symptoms were documented for location, severity, and duration. There were no reports of difficulty administering Anaphylm to subjects in the study. Following allergen exposure, all subjects reported symptoms consistent with those experienced with their known allergies. Approximately twenty-five percent of subjects reported swelling of their tongues, lips, cheeks, and/or throat. Additional mucosal allergic symptoms included tingling, pain, and nasal congestion. Ninety-four percent of subjects were categorized as having moderate or severe symptoms according to the pre-defined oral severity score. The median time for complete symptom resolution for subjects in the study following administration of Anaphylm was twelve minutes. This is faster than the median time to complete symptom resolution at screening, which was seventy-four minutes. After Anaphylm administration, symptoms began resolving as early as two minutes in some subjects and fifty percent of all symptoms across all subjects were resolved by five minutes. Importantly, all instances of symptomatic swelling were completely resolved by five minutes after administration of Anaphylm. Story Continues Both primary and secondary endpoints of the OAS challenge study were successfully met with no significant differences found between Anaphylm PK results in subjects with and without allergen exposure. Anaphylm PK results in subjects with allergen exposure remained similar to previous profiles from the Company’s pivotal study in healthy subjects. The time to maximum plasma concentration, or Tmax, remained at twelve minutes in subjects with and without allergen exposure following a single dose of Anaphylm. The maximum plasma concentration, or Cmax, was comparable between Anaphylm administered with and without allergen exposure. In addition, Anaphylm was safe and well-tolerated with all adverse events categorized as mild or moderate and resolving without medical intervention. “Symptom relief is the most real-world scenario whereby subjects know their rescue product is working,” said Jay Lieberman, M.D., Professor at the University of Tennessee Health Science Center, physician at LeBonheur Children’s Hospital, and Chair of the Annual Meeting Program for the American College of Allergy, Asthma, and Immunology (ACAAI). “I am reassured by the speed of symptom relief seen in the OAS Study and by the continued and consistent rapid absorption profile of Anaphylm. These data provide strong evidence that Anaphylm could provide a reliable alternative to the approved epinephrine medical devices currently available to patients.” "We are extremely pleased with the positive results from our OAS challenge study, which further validate Anaphylm's potential as a game-changing treatment option for severe allergic reactions, including anaphylaxis, if approved by the FDA" said Daniel Barber, President and Chief Executive Officer of Aquestive. "These results demonstrate that Anaphylm maintains its consistent PK and PD profile even when administered during oral allergic conditions, such as swelling. In addition, Anaphylm demonstrated its ability to resolve symptoms following the introduction of an oral allergen. This is a critical finding as we advance towards our NDA submission, as it confirms Anaphylm's potential effectiveness in real-world allergic scenarios." Aquestive has requested a pre-NDA meeting with the FDA and expects to meet with the FDA in the fourth quarter of 2024. The Company remains on track to commence a pediatric study in subjects weighing 30 kgs and above in the fourth quarter 2024 and to submit a New Drug Application (NDA) to the FDA in the first quarter 2025. If approved by the FDA, Aquestive is poised to initiate a full product launch of Anaphylm in the first quarter of 2026. A presentation containing additional information about this topline data is available on the Events and Presentations page within the Investor page of the Aquestive website. About Anaphylm™ (epinephrine) Sublingual Film Anaphylm™ (epinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. Anaphylm is similar in size to a postage stamp, weighs less than an ounce, and begins to dissolve on contact. No water or swallowing is required for administration. The packaging for Anaphylm is thinner and smaller than an average credit card, can be carried in a pocket, and is designed to withstand weather excursions such as exposure to rain and/or sunlight. The Anaphylm trade name for AQST-109 has been conditionally approved by the FDA. Final approval of the Anaphylm proprietary name is conditioned on FDA approval of the product candidate. About Aquestive Therapeutics Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products marketed by the Company and its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an earlier stage epinephrine prodrug topical gel for various dermatology conditions. For more information, visit Aquestive.com and follow us on LinkedIn. Forward-Looking Statement Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of our product candidate Anaphylm™ (epinephrine) Sublingual Film through clinical development and approval by the FDA, including the timing of submission of supporting and pediatric clinical studies, holding a pre-NDA meeting with the FDA and filing the NDA for Anaphylm with the FDA, and the following launch of Anaphylm, if approved by the FDA; that the results of the Company’s clinical studies for Anaphylm are sufficient to support submission of the NDA for approval of Anaphylm by the FDA; the potential indications and potential benefits our product candidates could bring to patients; and business strategies, market opportunities, and other statements that are not historical facts. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with our development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials and plans, including those relating to Anaphylm (including for pediatric patients); risk of delays in advancement of the regulatory approval process through the FDA of our product candidates, including the filing of the respective NDAs, including for Anaphylm, or the failure to receive FDA approval at all of any of these product candidates; risk of the Company’s ability to generate sufficient clinical data for approval of our product candidates, including with respect to our pharmacokinetic and pharmacodynamic comparability submission for FDA approval of Anaphylm; risk of the Company’s ability to address the FDA’s comments on the Company’s clinical trials and other concerns identified in the FDA Type C meeting minutes for Anaphylm, including the risk that the FDA may require additional clinical studies for approval of Anaphylm; risks and uncertainties inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations); risk of sufficient capital and cash resources, including sufficient access to available debt and equity financing, including under our ATM facility and the Lincoln Park Purchase Agreement, and revenues from operations, to satisfy all of our short-term and longer-term liquidity and cash requirements and other cash needs, at the times and in the amounts needed, including to fund commercialization activities relating to fund future clinical development and commercial activities for our product candidates, including Anaphylm, should these product candidates be approved by the FDA; risk of eroding market share for Suboxone® and risk as a sunsetting product, which accounts for the substantial part of our current operating revenue; risk of default of our debt instruments; risks related to the outsourcing of certain sales, marketing and other operational and staff functions to third parties; risk of the rate and degree of market acceptance in the U.S. of Anaphylm and our other product candidates, should these product candidates be approved by the FDA, and for our licensed products in the U.S. and abroad; risk of the success of any competing products including generics; risk of the size and growth of our product markets; risk of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; risks associated with intellectual property rights and infringement claims relating to our products; risk that our patent applications for our product candidates, including for Anaphylm, will not be timely issued, or issued at all, by the U.S. Patent and Trademark Office; risk of unexpected patent developments; risk of legislation and regulatory actions and changes in laws or regulations affecting our business including relating to our products and products candidates and product pricing, reimbursement or access therefor; risk of loss of significant customers; risks related to claims and legal proceedings against Aquestive including patent infringement, securities, business torts, investigative, product safety or efficacy and antitrust litigation matters; risk of product recalls and withdrawals; risks related to any disruptions in our information technology networks and systems, including the impact of cybersecurity attacks; risk of increased cybersecurity attacks and data accessibility disruptions due to remote working arrangements; risk of adverse developments affecting the financial services industry; risks related to inflation and rising interest rates; risks related to the impact of the COVID-19 global pandemic and other pandemic diseases on our business, including with respect to our clinical trials and the site initiation, patient enrollment and timing and adequacy of those clinical trials, regulatory submissions and regulatory reviews and approvals of our product candidates, availability of pharmaceutical ingredients and other raw materials used in our products and product candidates, supply chain, manufacture and distribution of our products and product candidates; risks and uncertainties related to general economic, political (including the Ukraine and Israel wars and other acts of war and terrorism), business, industry, regulatory, financial and market conditions and other unusual items; and other uncertainties affecting us including those described in the "Risk Factors" section and in other sections included in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law. PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners. Investor Inquiries ICR Healthcare Stephanie Carrington stephanie.carrington@icrhealthcare.com 646-277-1282 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories
Content Reference URL	None

Data Source Name	Yahoo Finance News
Data Source Type	news
Data Source URL	https://finance.yahoo.com/
Description	Yahoo! Finance is a media property that is part of the Yahoo! network. It provides financial news, data and commentary including stock quotes, press releases, financial reports, and original content. It also offers some online tools for personal finance management.
Weight	10

DJDT

Versions

Package	Name	Version
Django		5.0.3
Python		3.11.8
coverage	Coverage	7.4.4
debug_toolbar	Debug Toolbar	4.3.0
django_extensions	Django Extensions	3.2.3
grappelli	Grappelli	3.0.8

Time

Resource usage

Resource	Value
User CPU time	32.729 msec
System CPU time	0.030 msec
Total CPU time	32.759 msec
Elapsed time	41.304 msec
Context switches	5 voluntary, 0 involuntary

Browser timing

Timing attribute	Timeline	Milliseconds since navigation start (+length)

Settings from app.settings

Setting	Value
ABSOLUTE_URL_OVERRIDES	`{}`
ADMINS	`[]`
ALLOWED_HOSTS	`['*']`
ALPACA_API	`'********************'`
APPEND_SLASH	`True`
AUTH0_CLIENT_ID	`None`
AUTH0_CLIENT_SECRET	`'********************'`
AUTH0_DOMAIN	`None`
AUTHENTICATION_BACKENDS	`['django.contrib.auth.backends.ModelBackend']`
AUTH_PASSWORD_VALIDATORS	`'********************'`
AUTH_USER_MODEL	`'auth.User'`
BASE_DIR	`PosixPath('/mnt/disks/pennyloupe_disk/pennyloupe')`
CACHES	`{'default': {'BACKEND': 'django.core.cache.backends.filebased.FileBasedCache', 'LOCATION': '/var/tmp/django_cache'}}`
CACHE_MIDDLEWARE_ALIAS	`'default'`
CACHE_MIDDLEWARE_KEY_PREFIX	`'********************'`
CACHE_MIDDLEWARE_SECONDS	`600`
CELERY_BROKER_URL	`'redis://localhost:6379'`
CELERY_RESULT_BACKEND	`'redis://localhost:6379'`
CSRF_COOKIE_AGE	`31449600`
CSRF_COOKIE_DOMAIN	`None`
CSRF_COOKIE_HTTPONLY	`False`
CSRF_COOKIE_NAME	`'csrftoken'`
CSRF_COOKIE_PATH	`'/'`
CSRF_COOKIE_SAMESITE	`'Lax'`
CSRF_COOKIE_SECURE	`False`
CSRF_FAILURE_VIEW	`'django.views.csrf.csrf_failure'`
CSRF_HEADER_NAME	`'HTTP_X_CSRFTOKEN'`
CSRF_TRUSTED_ORIGINS	`[]`
CSRF_USE_SESSIONS	`False`
DATABASES	`{'default': {'ATOMIC_REQUESTS': False, 'AUTOCOMMIT': True, 'CONN_HEALTH_CHECKS': True, 'CONN_MAX_AGE': 600, 'ENGINE': 'django.db.backends.postgresql', 'HOST': '34.125.28.12', 'NAME': 'pennyloupe', 'OPTIONS': {'sslmode': 'require'}, 'PASSWORD': '********************', 'PORT': 5432, 'TEST': {'CHARSET': None, 'COLLATION': None, 'MIGRATE': True, 'MIRROR': None, 'NAME': None}, 'TIME_ZONE': None, 'USER': 'pennyloupe'}}`
DATABASE_ROUTERS	`[]`
DATA_UPLOAD_MAX_MEMORY_SIZE	`2621440`
DATA_UPLOAD_MAX_NUMBER_FIELDS	`1000`
DATA_UPLOAD_MAX_NUMBER_FILES	`100`
DATETIME_FORMAT	`'N j, Y, P'`
DATETIME_INPUT_FORMATS	`['%Y-%m-%d %H:%M:%S', '%Y-%m-%d %H:%M:%S.%f', '%Y-%m-%d %H:%M', '%m/%d/%Y %H:%M:%S', '%m/%d/%Y %H:%M:%S.%f', '%m/%d/%Y %H:%M', '%m/%d/%y %H:%M:%S', '%m/%d/%y %H:%M:%S.%f', '%m/%d/%y %H:%M']`
DATE_FORMAT	`'N j, Y'`
DATE_INPUT_FORMATS	`['%Y-%m-%d', '%m/%d/%Y', '%m/%d/%y', '%b %d %Y', '%b %d, %Y', '%d %b %Y', '%d %b, %Y', '%B %d %Y', '%B %d, %Y', '%d %B %Y', '%d %B, %Y']`
DEBUG	`True`
DEBUG_PROPAGATE_EXCEPTIONS	`False`
DEBUG_TOOLBAR_CONFIG	`{'SHOW_TOOLBAR_CALLBACK': <function <lambda> at 0x7ff664cdbec0>}`
DECIMAL_SEPARATOR	`'.'`
DEFAULT_AUTO_FIELD	`'django.db.models.BigAutoField'`
DEFAULT_CHARSET	`'utf-8'`
DEFAULT_EXCEPTION_REPORTER	`'django.views.debug.ExceptionReporter'`
DEFAULT_EXCEPTION_REPORTER_FILTER	`'django.views.debug.SafeExceptionReporterFilter'`
DEFAULT_FILE_STORAGE	`'django.core.files.storage.FileSystemStorage'`
DEFAULT_FROM_EMAIL	`'webmaster@localhost'`
DEFAULT_INDEX_TABLESPACE	`''`
DEFAULT_TABLESPACE	`''`
DISALLOWED_USER_AGENTS	`[]`
EMAIL_BACKEND	`'django.core.mail.backends.smtp.EmailBackend'`
EMAIL_HOST	`'localhost'`
EMAIL_HOST_PASSWORD	`'********************'`
EMAIL_HOST_USER	`''`
EMAIL_PORT	`25`
EMAIL_SSL_CERTFILE	`None`
EMAIL_SSL_KEYFILE	`'********************'`
EMAIL_SUBJECT_PREFIX	`'[Django] '`
EMAIL_TIMEOUT	`None`
EMAIL_USE_LOCALTIME	`False`
EMAIL_USE_SSL	`False`
EMAIL_USE_TLS	`False`
FIELD_ENCRYPTION_KEY	`'********************'`
FILE_UPLOAD_DIRECTORY_PERMISSIONS	`None`
FILE_UPLOAD_HANDLERS	`['django.core.files.uploadhandler.MemoryFileUploadHandler', 'django.core.files.uploadhandler.TemporaryFileUploadHandler']`
FILE_UPLOAD_MAX_MEMORY_SIZE	`2621440`
FILE_UPLOAD_PERMISSIONS	`420`
FILE_UPLOAD_TEMP_DIR	`None`
FIRST_DAY_OF_WEEK	`0`
FIXTURE_DIRS	`[]`
FORCE_SCRIPT_NAME	`None`
FORMAT_MODULE_PATH	`None`
FORMS_URLFIELD_ASSUME_HTTPS	`False`
FORM_RENDERER	`'django.forms.renderers.DjangoTemplates'`
GRAPPELLI_ADMIN_TITLE	`'Penny Loupe'`
GRAPPELLI_AUTOCOMPLETE_SEARCH_FIELDS	`{'auth': {'user': ('id__iexact', 'username__icontains')}}`
IGNORABLE_404_URLS	`[]`
INSTALLED_APPS	`['coverage', 'grappelli', 'django.contrib.admin', 'django.contrib.auth', 'django.contrib.contenttypes', 'django.contrib.humanize', 'django.contrib.messages', 'django.contrib.postgres', 'django.contrib.sessions', 'django.contrib.staticfiles', 'django_htmx', 'app.core.apps.CoreConfig', 'django_extensions', 'debug_toolbar']`
INTERNAL_IPS	`['127.0.0.1']`
LANGUAGES	`[('en', 'English')]`
LANGUAGES_BIDI	`['he', 'ar', 'ar-dz', 'ckb', 'fa', 'ug', 'ur']`
LANGUAGE_CODE	`'en-us'`
LANGUAGE_COOKIE_AGE	`None`
LANGUAGE_COOKIE_DOMAIN	`None`
LANGUAGE_COOKIE_HTTPONLY	`False`
LANGUAGE_COOKIE_NAME	`'django_language'`
LANGUAGE_COOKIE_PATH	`'/'`
LANGUAGE_COOKIE_SAMESITE	`None`
LANGUAGE_COOKIE_SECURE	`False`
LOCALE_PATHS	`[]`
LOGGING	`{}`
LOGGING_CONFIG	`'logging.config.dictConfig'`
LOGIN_REDIRECT_URL	`'/accounts/profile/'`
LOGIN_URL	`'/accounts/login/'`
LOGOUT_REDIRECT_URL	`None`
MANAGERS	`[]`
MEDIA_ROOT	`PosixPath('/mnt/disks/pennyloupe_disk/pennyloupe/media')`
MEDIA_URL	`'/media/'`
MESSAGE_STORAGE	`'django.contrib.messages.storage.fallback.FallbackStorage'`
MIDDLEWARE	['django.middleware.security.SecurityMiddleware', 'whitenoise.middleware.WhiteNoiseMiddleware', 'django.contrib.sessions.middleware.SessionMiddleware', 'django.middleware.cache.UpdateCacheMiddleware', 'django.middleware.common.CommonMiddleware', 'django.middleware.csrf.CsrfViewMiddleware', 'django.contrib.auth.middleware.AuthenticationMiddleware', 'django.contrib.messages.middleware.MessageMiddleware', 'django.middleware.clickjacking.XFrameOptionsMiddleware', 'django_htmx.middleware.HtmxMiddleware', 'debug_toolbar.middleware.DebugToolbarMiddleware']
MIGRATION_MODULES	`{}`
MONTH_DAY_FORMAT	`'F j'`
NUMBER_GROUPING	`0`
OPENAI_API_KEY	`'********************'`
PASSWORD_HASHERS	`'********************'`
PASSWORD_RESET_TIMEOUT	`'********************'`
POLYGON_API_KEY	`'********************'`
PREPEND_WWW	`False`
QT_API_KEY	`'********************'`
QT_APP_ID	`'13d3cbab'`
QT_PASSWORD	`'********************'`
QT_USERNAME	`'kevin+dev3@pennyloupe.com'`
ROOT_URLCONF	`'app.urls'`
SCRAPER_API_KEY	`'********************'`
SECRET_KEY	`'********************'`
SECRET_KEY_FALLBACKS	`'********************'`
SECURE_CONTENT_TYPE_NOSNIFF	`True`
SECURE_CROSS_ORIGIN_OPENER_POLICY	`'same-origin'`
SECURE_HSTS_INCLUDE_SUBDOMAINS	`False`
SECURE_HSTS_PRELOAD	`False`
SECURE_HSTS_SECONDS	`0`
SECURE_PROXY_SSL_HEADER	`None`
SECURE_REDIRECT_EXEMPT	`[]`
SECURE_REFERRER_POLICY	`'same-origin'`
SECURE_SSL_HOST	`None`
SECURE_SSL_REDIRECT	`False`
SERVER_EMAIL	`'root@localhost'`
SESSION_CACHE_ALIAS	`'default'`
SESSION_COOKIE_AGE	`1209600`
SESSION_COOKIE_DOMAIN	`None`
SESSION_COOKIE_HTTPONLY	`True`
SESSION_COOKIE_NAME	`'sessionid'`
SESSION_COOKIE_PATH	`'/'`
SESSION_COOKIE_SAMESITE	`'Lax'`
SESSION_COOKIE_SECURE	`False`
SESSION_ENGINE	`'django.contrib.sessions.backends.db'`
SESSION_EXPIRE_AT_BROWSER_CLOSE	`False`
SESSION_FILE_PATH	`None`
SESSION_SAVE_EVERY_REQUEST	`False`
SESSION_SERIALIZER	`'django.contrib.sessions.serializers.JSONSerializer'`
SETTINGS_MODULE	`'app.settings'`
SHORT_DATETIME_FORMAT	`'m/d/Y P'`
SHORT_DATE_FORMAT	`'m/d/Y'`
SIGNING_BACKEND	`'django.core.signing.TimestampSigner'`
SILENCED_SYSTEM_CHECKS	`[]`
SQL_FILES_DIR	`'/mnt/disks/pennyloupe_disk/pennyloupe/app/core/sql'`
STATICFILES_DIRS	`[]`
STATICFILES_FINDERS	`['django.contrib.staticfiles.finders.FileSystemFinder', 'django.contrib.staticfiles.finders.AppDirectoriesFinder']`
STATICFILES_STORAGE	`'django.contrib.staticfiles.storage.StaticFilesStorage'`
STATIC_ROOT	`PosixPath('/mnt/disks/pennyloupe_disk/pennyloupe/static')`
STATIC_URL	`'/static/'`
STORAGES	`{'default': {'BACKEND': 'django.core.files.storage.FileSystemStorage'}, 'staticfiles': {'BACKEND': 'django.contrib.staticfiles.storage.StaticFilesStorage'}}`
TEMPLATES	`[{'APP_DIRS': True, 'BACKEND': 'django.template.backends.django.DjangoTemplates', 'DIRS': ['templates'], 'OPTIONS': {'context_processors': ['django.template.context_processors.debug', 'django.template.context_processors.request', 'django.contrib.auth.context_processors.auth', 'django.contrib.messages.context_processors.messages']}}]`
TEST_NON_SERIALIZED_APPS	`[]`
TEST_RUNNER	`'django.test.runner.DiscoverRunner'`
THOUSAND_SEPARATOR	`','`
TIME_FORMAT	`'P'`
TIME_INPUT_FORMATS	`['%H:%M:%S', '%H:%M:%S.%f', '%H:%M']`
TIME_ZONE	`'UTC'`
USE_I18N	`True`
USE_THOUSAND_SEPARATOR	`False`
USE_TZ	`True`
USE_X_FORWARDED_HOST	`False`
USE_X_FORWARDED_PORT	`False`
WSGI_APPLICATION	`'app.wsgi.application'`
X_FRAME_OPTIONS	`'DENY'`
YEAR_MONTH_FORMAT	`'F Y'`

Headers

Request headers

Key	Value
Accept	/
Accept-Encoding	gzip, br, zstd, deflate
Host	pennyloupe.com
User-Agent	Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)

Response headers

Key	Value
Content-Type	text/html; charset=utf-8

WSGI environ

Since the WSGI environ inherits the environment of the server, only a significant subset is shown below.

Key	Value
CONTENT_LENGTH
CONTENT_TYPE
PATH_INFO	/ticker/AQST/content/3567758
QUERY_STRING
REMOTE_ADDR	18.224.32.173
REQUEST_METHOD	GET
SCRIPT_NAME
SERVER_NAME	pennyloupe.com
SERVER_PORT	443
SERVER_PROTOCOL	HTTP/1.1

Request

View information

View function	Arguments	Keyword arguments	URL name
`app.core.views.app.ticker_content_detail`	`()`	`{'content_id': 3567758, 'ticker': 'AQST'}`	`ticker_content_detail`

No cookies

No session data

No GET data

No POST data

SQL queries from 1 connection

default 8.52 ms (3 queries )

	Query		Timeline	Time (ms)	Action
		SELECT "pl_content"."created_dt", "pl_content"."updated_dt", "pl_content"."status_id", "pl_content"."id", "pl_content"."key", "pl_content"."fetch_ref_id", "pl_content"."ticker", "pl_content"."publish_dt", "pl_content"."external_id", "pl_content"."published_by", "pl_content"."title", "pl_content"."summary", "pl_content"."tags", "pl_content"."url", "pl_content"."author", "pl_content"."author_reputation_score", "pl_content"."content_length", "pl_content"."sentiment_positive", "pl_content"."sentiment_negative", "pl_content"."sentiment_neutral", "pl_content"."sentiment", "pl_content"."relevance_score", "pl_content"."votes_positive", "pl_content"."votes_negative", "pl_content"."is_processing_flag", "pl_content"."data_source_id", "pl_content"."publisher_id" FROM "pl_content" WHERE "pl_content"."id" = 3567758 LIMIT 21SELECT ••• FROM "pl_content" WHERE "pl_content"."id" = 3567758 LIMIT 21		1.90
		Connection: default Transaction status: Idle /mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124) return self.get_response(request) /mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43) return self.get_response(request) /mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(1405) content = Content.objects.get(id=content_id)
		SELECT "pl_content_content"."created_dt", "pl_content_content"."updated_dt", "pl_content_content"."status_id", "pl_content_content"."id", "pl_content_content"."key", "pl_content_content"."content", "pl_content_content"."content_ref_url", "pl_content_content"."content_id" FROM "pl_content_content" WHERE "pl_content_content"."content_id" = 3567758 ORDER BY "pl_content_content"."id" ASC LIMIT 1SELECT ••• FROM "pl_content_content" WHERE "pl_content_content"."content_id" = 3567758 ORDER BY "pl_content_content"."id" ASC LIMIT 1		5.76
		Connection: default Transaction status: Idle /mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124) return self.get_response(request) /mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43) return self.get_response(request) /mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(1411) content_content = ContentContent.objects.filter(details=content).first()
		SELECT "pl_data_source"."created_dt", "pl_data_source"."updated_dt", "pl_data_source"."status_id", "pl_data_source"."id", "pl_data_source"."name", "pl_data_source"."type", "pl_data_source"."url", "pl_data_source"."description", "pl_data_source"."weight", "pl_data_source"."class_name", "pl_data_source"."class_params_json" FROM "pl_data_source" WHERE "pl_data_source"."id" = 2 LIMIT 21SELECT ••• FROM "pl_data_source" WHERE "pl_data_source"."id" = 2 LIMIT 21		0.85
		Connection: default Transaction status: Idle /mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124) return self.get_response(request) /mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43) return self.get_response(request) /mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(1415) data_source = content.data_source

Static files (717 found, 2 used)

Static file paths

None

Static file apps

grappelli
django.contrib.admin
django_htmx
app.core
django_extensions
debug_toolbar

Static files

css/pennyloupe.css: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/static/css/pennyloupe.css
img/penny_loupe_logo.png: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/static/img/penny_loupe_logo.png

django.contrib.staticfiles.finders.AppDirectoriesFinder (717 files)

Templates (6 rendered)

Template path

templates

Templates

ticker_content_detail.html: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/templates/ticker_content_detail.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7ff64a84f880>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/AQST/content/3567758'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7ff64a84f420>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7ff64a84f420>>'} {'content_detail': {'content': <Content: Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film - >, 'content_content': <ContentContent: Content ID: 1884608>, 'data_source': <DataSource: Yahoo Finance News>, 'publisher': None}, 'ticker': 'AQST'}
base.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/base.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7ff64a84f880>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/AQST/content/3567758'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7ff64a84f420>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7ff64a84f420>>'} {'content_detail': {'content': <Content: Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film - >, 'content_content': <ContentContent: Content ID: 1884608>, 'data_source': <DataSource: Yahoo Finance News>, 'publisher': None}, 'ticker': 'AQST'}
components/leftnav.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/components/leftnav.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7ff64a84f880>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/AQST/content/3567758'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7ff64a84f420>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7ff64a84f420>>'} {'content_detail': {'content': <Content: Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film - >, 'content_content': <ContentContent: Content ID: 1884608>, 'data_source': <DataSource: Yahoo Finance News>, 'publisher': None}, 'ticker': 'AQST'} {'block': <Block Node: leftnav. Contents: [<TextNode: '\n <div'>, <IncludeNode: template=<FilterExpression '"components/leftnav.html"'>>, <TextNode: '\n </di'>]>}
components/header.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/components/header.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7ff64a84f880>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/AQST/content/3567758'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7ff64a84f420>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7ff64a84f420>>'} {'content_detail': {'content': <Content: Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film - >, 'content_content': <ContentContent: Content ID: 1884608>, 'data_source': <DataSource: Yahoo Finance News>, 'publisher': None}, 'ticker': 'AQST'} {'block': <Block Node: header. Contents: [<TextNode: '\n\n '>, <IncludeNode: template=<FilterExpression '"components/header.html"'>>, <TextNode: '\n\n '>]>}
components/ticker_subnav.html: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/templates/components/ticker_subnav.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7ff64a84f880>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/AQST/content/3567758'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7ff64a84f420>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7ff64a84f420>>'} {'content_detail': {'content': <Content: Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film - >, 'content_content': <ContentContent: Content ID: 1884608>, 'data_source': <DataSource: Yahoo Finance News>, 'publisher': None}, 'ticker': 'AQST'} {'block': <Block Node: content. Contents: [<TextNode: '\n\n <div class="uk-flex'>, <IncludeNode: template=<FilterExpression '"components/ticker_subnav.html"'>>, <TextNode: '\n <!-- /SUB NAV--'>, <Variable Node: content_detail.content.title>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.id>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.external_id>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.author>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.publish_dt>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.summary>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.tags>, <TextNode: '</td>\n '>, <IfNode>, <TextNode: '\n '>, <Variable Node: content_detail.content.sentiment_negative>, <TextNode: '   \n '>, <Variable Node: content_detail.content.sentiment_neutral>, <TextNode: '   \n '>, <Variable Node: content_detail.content.sentiment_positive>, <TextNode: '<br/>\n '>, <django.template.defaulttags.WidthRatioNode object at 0x7ff656abd450>, <TextNode: '%;"></div>\n '>, <Variable Node: content_detail.content.sentiment_neutral>, <TextNode: '" style="width:'>, <django.template.defaulttags.WidthRatioNode object at 0x7ff653f5c250>, <TextNode: '%;"></div>\n '>, <Variable Node: content_detail.content.sentiment_positive>, <TextNode: '" style="width:'>, <django.template.defaulttags.WidthRatioNode object at 0x7ff653f2c510>, <TextNode: '%;"></div>\n '>, <Variable Node: content_detail.content.relevance_score>, <TextNode: '</td>\n '>, <IfNode>, <TextNode: '\n '>, <IfNode>, <TextNode: '\n <li clas'>, <Variable Node: content_detail.data_source.name>, <TextNode: '</td>\n '>, <Variable Node: content_detail.data_source.type>, <TextNode: '</td>\n '>, <Variable Node: content_detail.data_source.url>, <TextNode: '" target="_blank">'>, <Variable Node: content_detail.data_source.url>, <TextNode: '</a></td>\n '>, <Variable Node: content_detail.data_source.description>, <TextNode: '</td>\n '>, <Variable Node: content_detail.data_source.weight>, <TextNode: '</td>\n '>]>} {'ticker': 'AQST'}
components/footer.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/components/footer.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7ff64a84f880>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/AQST/content/3567758'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7ff64a84f420>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7ff64a84f420>>'} {'content_detail': {'content': <Content: Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film - >, 'content_content': <ContentContent: Content ID: 1884608>, 'data_source': <DataSource: Yahoo Finance News>, 'publisher': None}, 'ticker': 'AQST'} {'block': <Block Node: footer. Contents: [<TextNode: '\n '>, <IncludeNode: template=<FilterExpression '"components/footer.html"'>>, <TextNode: '\n '>]>}

Context processors

django.template.context_processors.csrf: Toggle context
{'csrf_token': <SimpleLazyObject: <function csrf.<locals>._get_val at 0x7ff64a84f880>>}
django.template.context_processors.debug: Toggle context
{}
django.template.context_processors.request: Toggle context
{'request': <WSGIRequest: GET '/ticker/AQST/content/3567758'>}
django.contrib.auth.context_processors.auth: Toggle context
{'user': <SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7ff64a84f420>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7ff64a84f420>>)}
django.contrib.messages.context_processors.messages: Toggle context
{'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/AQST/content/3567758'>>, 'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30, 'ERROR': 40}}

Cache calls from 1 backend

Summary

Total calls	Total time	Cache hits	Cache misses
0	0 ms	0	0

Commands

add	get	set	get_or_set	touch	delete	clear	get_many	set_many	delete_many	has_key	incr	decr	incr_version	decr_version
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Signals

Signal	Receivers
class_prepared
connection_created	register_type_handlers
got_request_exception
m2m_changed
post_delete
post_init
post_migrate	create_permissions, create_contenttypes
post_save	create_initial_trade_position
pre_delete
pre_init
pre_migrate	inject_rename_contenttypes_operations
pre_save
request_finished	close_old_connections, close_caches, reset_urlconf
request_started	reset_queries, close_old_connections
setting_changed	reset_cache, clear_cache_handlers, update_installed_apps, update_connections_time_zone, clear_routers_cache, reset_template_engines, storages_changed, clear_serializers_cache, language_changed, localize_settings_changed, file_storage_changed, complex_setting_changed, root_urlconf_changed, static_storage_changed, static_finders_changed, auth_password_validators_changed, user_model_swapped, update_toolbar_config, reset_hashers, update_level_tags, uninstall_if_needed, clear_caches, StaticFilesStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties

Path	Location
.DS_Store	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/.DS_Store
grappelli/.DS_Store	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/.DS_Store
grappelli/js/grappelli.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/grappelli.js
grappelli/js/jquery.grp_related_m2m.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_related_m2m.js
grappelli/js/jquery.grp_autocomplete_fk.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_autocomplete_fk.js
grappelli/js/jquery.grp_autocomplete_generic.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_autocomplete_generic.js
grappelli/js/jquery.grp_timepicker.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_timepicker.js
grappelli/js/jquery.grp_collapsible_group.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_collapsible_group.js
grappelli/js/jquery.grp_related_generic.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_related_generic.js
grappelli/js/jquery.grp_related_fk.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_related_fk.js
grappelli/js/jquery.grp_collapsible.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_collapsible.js
grappelli/js/grappelli.min.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/grappelli.min.js
grappelli/js/jquery.grp_autocomplete_m2m.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_autocomplete_m2m.js
grappelli/js/jquery.grp_inline.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_inline.js
grappelli/images/spritesheet-1694777276.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/spritesheet-1694777276.png
grappelli/images/backgrounds/loading-small.gif	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/loading-small.gif
grappelli/images/backgrounds/changelist-results.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/changelist-results.png
grappelli/images/backgrounds/ui-sortable-placeholder.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/ui-sortable-placeholder.png
grappelli/images/backgrounds/nav-grabber.gif	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/nav-grabber.gif
grappelli/images/backgrounds/messagelist.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/messagelist.png
grappelli/images/icons/ui-datepicker-next.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/ui-datepicker-next.png
grappelli/images/icons/link-external-small_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/link-external-small_hover.png
grappelli/images/icons/tools-arrow-up-handler_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-arrow-up-handler_hover.png
grappelli/images/icons/date-hierarchy-back.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/date-hierarchy-back.png
grappelli/images/icons/tools-delete-handler-predelete.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-delete-handler-predelete.png
grappelli/images/icons/breadcrumbs-rtl.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/breadcrumbs-rtl.png
grappelli/images/icons/datepicker_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/datepicker_hover.png
grappelli/images/icons/tools-trash-handler_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-trash-handler_hover.png
grappelli/images/icons/selector-add-m2m-vertical_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/selector-add-m2m-vertical_hover.png
grappelli/images/icons/tools-related-remove-handler-small_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-related-remove-handler-small_hover.png
grappelli/images/icons/sorted-descending.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/sorted-descending.png
grappelli/images/icons/breadcrumbs_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/breadcrumbs_hover.png
grappelli/images/icons/tools-viewsite-link_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-viewsite-link_hover.png
grappelli/images/icons/object-tools-add-link.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/object-tools-add-link.png
grappelli/images/icons/tools-related-edit-handler-small-disabled.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-related-edit-handler-small-disabled.png
grappelli/images/icons/tools-related-remove-handler-small-disabled.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-related-remove-handler-small-disabled.png
grappelli/images/icons/sorted-ascending.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/sorted-ascending.png
grappelli/images/icons/link-internal-rtl-small_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/link-internal-rtl-small_hover.png
grappelli/images/icons/pulldown-handler_selected.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/pulldown-handler_selected.png
grappelli/images/icons/tools-delete-handler_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-delete-handler_hover.png

Content Detail

Versions

Time

Resource usage

Browser timing

Settings from app.settings

Headers

Request headers

Response headers

WSGI environ

Request

View information

No cookies

No session data

No GET data

No POST data

SQL queries from 1 connection

Static files (717 found, 2 used)

Static file paths

Static file apps

Static files

django.contrib.staticfiles.finders.AppDirectoriesFinder (717 files)

Templates (6 rendered)

Template path

Templates

Context processors

Cache calls from 1 backend

Summary

Commands

Signals